Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS-102 in advanced refractory pancreatic adenocarcinoma
NCT04923529Phase 2Completed
- Sponsor
- The University of Hong Kong
- Start
- Mar 2021
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trifluridine + tipiracil in pancreatic adenocarcinoma (PDAC), sponsored by The University of Hong Kong. Started Mar 2021; status: completed.
02
Drugs
trifluridine + tipiracil
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04923529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04923529.